Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30701004 | 1.00 | SLC6A4 (0.51) | SLC6A4SLC6A2 | |
| SCHEMBL4991130 | 0.86 | SLC6A2 (0.56) | SLC6A4SLC6A2 | |
| SCHEMBL734140 | 0.83 | SLC6A4 (0.51) | SLC6A4SLC6A2 | |
| SCHEMBL6689744 | 0.82 | SLC6A4 (0.48) | SLC6A4SLC6A2 | |
| SCHEMBL30641149 | 0.81 | SLC6A2 (0.50) | SLC6A4SLC6A2 | |
| SCHEMBL24729036 | 0.79 | SLC6A2 (0.49) | SLC6A4SLC6A2 | |
| SCHEMBL599150 | 0.79 | SLC6A2 (0.49) | SLC6A4SLC6A2 | |
| SCHEMBL30460003 | 0.79 | SLC6A4 (0.50) | SLC6A4SLC6A2 | |
| SCHEMBL1841921 | 0.79 | SLC6A4 (0.50) | SLC6A4SLC6A2 | |
| SCHEMBL8573980 | 0.78 | SLC6A4 (0.53) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| US-5550239-A | REACTING TRIALKYLSILYL N-PENTYLPIPERAZINYLPYRIMIDINE DERIVATIVE WITH 4-AMINO-3-IODO-BENZENESULFONAMIDE COMPOUND IN PALLADIUM CATALYZED HETEROANNULATION STEP, REMOVING TRIALKYLSILYL GROUP WITH MINERAL ACID, BASIFYING | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0711769-A1 | Improved process for large-scale production of BMS 180048 and analogs | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-05-15 | — | — | EP | disclosed |
| EP-0022634-B1 | ACYLATED INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS AND DRUGS COMPRISING THEM | TEIJIN LIMITED (JP) | 1983-04-06 | — | — | EP | disclosed |
| EP-0022634-A1 | Acylated indole derivatives, processes for their preparation and pharmaceutical compositions and drugs comprising them | TEIJIN LIMITED (JP) | 1981-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | SLC6A4 4510/4885SLC6A2 4589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.